Natalizumab biosimilar for treating relapsing-remitting multiple sclerosis

Natalizumab biosimilar is being developed as a biosimilar medicine to the approved monoclonal antibody natalizumab and is proposed to be used to treat adult patients relapsing remitting multiple sclerosis (RRMS). Multiple sclerosis is an autoimmune condition where the body’s immune system attacks the brain and nerves. RRMS is characterised by attacks of new or increasing neurological symptoms, with intermittent periods of partial or complete recovery. Biosimilar medicines are biological therapies which have no clinically meaningful differences in efficacy, quality, and safety compared to the reference biologic product. Biosimilars are competitively priced to compete with the original product allowing them to be more widely available to the patients who need them.